A novel pretherapeutic gene expression-based risk score for treatment guidance in gastric cancer.

Bauer, L; Hapfelmeier, A; Blank, S; Reiche, M; Slotta-Huspenina, J; Jesinghaus, M; Novotny, A; Schmidt, T; Grosser, B; Kohlruss, M; Weichert, W; Ott, K; Keller, G

doi:10.1093/annonc/mdx685

2018

Zurück
Zurück zum Anfang der Trefferliste
Dauerhafter Link zum angezeigten Objekt

Titel:: A novel pretherapeutic gene expression-based risk score for treatment guidance in gastric cancer.
Dokumenttyp:: Journal Article
Autor(en):: Bauer, L; Hapfelmeier, A; Blank, S; Reiche, M; Slotta-Huspenina, J; Jesinghaus, M; Novotny, A; Schmidt, T; Grosser, B; Kohlruss, M; Weichert, W; Ott, K; Keller, G
Abstract:: Perioperative chemotherapy is an established treatment of advanced gastric cancer patients. Treatment selection is based on clinical staging (cT). We aimed to establish and validate a prognostic score including clinical and molecular factors, to optimize treatment decisions for these patients.We analyzed 626 carcinomas of the stomach and of the gastro-esophageal junction from two academic centers including primarily resected and pre-/perioperatively treated patients. Patients were divided into a training (N = 269) and validation (N = 357) set. Expression of 11 target genes was measured by quantitative PCR in resected tumors. A risk score to predict overall survival (OS) was generated and validated. Intra-tumoral heterogeneity was assessed by analyzing 50 tumor areas from 10 patients.A risk score including the expression of CCL5, CTNNB1, EXOSC3 and LZTR1 and the clinical parameters cT, tumor localization and histopathologic type suggested two groups with a significant difference in OS [hazard ratio (HR) 0.30; 95% confidence interval (CI) 0.17-0.52]. The risk score was successfully validated in an independent cohort (HR 0.32; 95% CI 0.21-0.51; P < 0.001) as well as in subgroups of primarily resected (HR 0.30; 95% CI 0.17-0.54; P < 0.001) and pre-/perioperatively treated patients (HR 0.37; 95% CI 0.17-0.81; P = 0.009). A significant difference in OS of high- and low-risk patients was also found in primarily resected patients with intestinal (HR 0.45; 95% CI 0.23-0.90; P = 0.020) and nonintestinal-type carcinomas (HR 0.1; 95% CI 0.02-0.42; P < 0.001). Intra-tumor heterogeneity analysis indicated a classification reliability of 95% for a supposed analysis of three biopsies.The identified risk score could substantially contribute to an improved management of gastric cancer patients in the context of perioperative chemotherapy.
Zeitschriftentitel:: Ann Oncol
Jahr:: 2018
Band / Volume:: 29
Heft / Issue:: 1
Seitenangaben Beitrag:: 127-132
Sprache:: eng
Volltext / DOI:: doi:10.1093/annonc/mdx685
PubMed:: http://view.ncbi.nlm.nih.gov/pubmed/29069277
Print-ISSN:: 0923-7534
TUM Einrichtung:: Chirurgische Klinik und Poliklinik; Institut für Allgemeine Pathologie und Pathologische Anatomie
BibTeX